• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Curacyte

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · August 29, 2011

Curacyte: Phase III Distributive Shock Trial (“PHOENIX trial”) Terminated for Futility

The PHOENIX trial is a European, placebo-controlled, Phase III study treating patients in catecholamine-resistant, distributive shock with the Nitric Oxide (NO) scavenger PHP / Hemoximer. The study …

News · March 28, 2011

Curacyte – PHOENIX Phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB

Munich, March, 28th 2011 - The PHOENIX trial is a European, placebocontrolled, Phase III study treating catecholamine-resistant patients in distributive shock with the Nitric Oxide (NO) scavenger …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact